Journal
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
Volume 68, Issue 4, Pages 348-351Publisher
INFORMA HEALTHCARE
DOI: 10.1080/00365510701604628
Keywords
amyotrophic lateral sclerosis; angiogenesis; endoglin; neurodegeneration; serum
Categories
Ask authors/readers for more resources
Objectives. Angiogenic mechanisms may have a role to play in the neurodegeneration observed in amyotrophic lateral sclerosis (ALS). The aim of the present study was to measure serum angiogenic factor endoglin (ENG) levels in patients with ALS. Material and methods. The study involved 25 ALS patients and 25 controls. Concentrations of ENG in serum samples were measured using a human Endoglin/CD105 ELISA kit (R&D Systems, Minneapolis, Minn., USA). Results. Serum ENG concentrations were 14% lower in the patients with ALS compared to controls (4.57 versus 3.97 ng/mL; p < 0.05). There was no significant difference in serum ENG levels between subgroups of patients with ALS subdivided depending on clinical state, type of ALS onset and duration of the disease (p > 0.05). The correlation between serum ENG levels and clinical parameters of ALS was not significant either (p > 0.05). Conclusions. Results indicate that ENG may be implicated in the pathomechanism of ALS. A decrease in ENG levels, as observed in this study, may accelerate neurodegeneration of motor neurons in ALS through chronic ischaemia caused by impaired perfusion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available